Cadence Pharmaceuticals' Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus ...( SAN DIEGO Nov. 8 /- Cadence Pharm...),Health

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Executive Vice President and Chief Medical Officer James Breitmeyer will present the corporate overview on Tuesday, November 13, 2007 at 8:00 am Eastern Time during the JMP Securities Healthcare Focus Conference in Boston.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcasts and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts:

William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relatio
'/>"/>